21
Participants
Start Date
September 16, 2021
Primary Completion Date
October 18, 2022
Study Completion Date
October 18, 2022
RNA antisense oligonucleotide for intravitreal injection
"QR-421a will be first administered to the fellow eye (as defined in the preceding study), and will be repeated every 6 months.~Treatment of the study eye (as defined in the preceding study) can commence 3 months (9 months for subjects from study PQ-421a-001) after the treatment of the fellow eye has been initiated and will be repeated every 6 months as well.~Continued subject treatment in this study will be pursued provided that the benefit-risk balance is positive for the individual subject."
Hôpital Gui de Chauliac - CHRU de Montpellier - Maladies Sensorielles Génétique, Montpellier
University of Michigan, Kellogg Eye Center, Ann Arbor
Centre de maladies rares CHNO des Quinze Vingts, Paris
Retina Foundation of the Southwest, Dallas
Casey Eye Institute, Oregon Health & Science University, Portland
Center for Clinical Research Operations, Massachusetts Eye and Ear, Boston
Centre for Innovative Medicine, Department of Paediatric Surgery, Montreal Children's Hospital at the McGill University Health Centre, Montreal
Lead Sponsor
Sepul Bio
INDUSTRY
Laboratoires Thea
INDUSTRY